Navion Neurosciences
Navion develops precision sodium-channel medicines for genetic epilepsy and chronic nerve pain.
01What it doesNavion develops precision sodium-channel medicines for genetic epilepsy and chronic nerve pain.Source-grounded · automated review · Explore ↗
Checked 2026-09-11 · Review due 2026-09-18
Read supporting source ↗Navion Neurosciences, Inc. announced first…
02Who is involvedEvidence still neededOpen review status ↗
Misleading wording. Document 0 says The Angelini Lumira Biosciences Fund led, with participation from 3B Future Health Fund, UVA LVG Seed Fund, Virginia Innovation Partnership Corporation, VTC Innovation Fund, and Navion management. The draft says 'five funds and Navion management,' but the document
03What happenedEvidence still neededOpen review status ↗
Supported as far as stated: document 0 says Navion announced a first closing of a USD 10.8 million seed financing round. No valuation is stated. However, the target date 2026-09-11 is not supported by the provided document text, so top-level eventMatch is false.
04Why it mattersThe funding supports preclinical drug programs, aiming to prepare data before human clinical development.Interpretation · Explore ↗
Navion Neurosciences · Financing Record
Explore source-linked visual explanations for Navion Neurosciences. Unsupported claims are withheld while source review continues.
Record 12097 · Recorded date: 2026-09-11
Explore company records →